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Multidrug resistant tuberculosis (MDR-TB) is a serious form of tuberculosis (TB). There is no recognized effective
treatment for MDR-TB, although there are a number of publications that have reported positive results for MDR-TB.
We performed a network meta-analysis to assess the efficacy and acceptability of potential antitubercular drugs. We
conducted a network meta-analysis of randomized controlled clinical trials to compare the efficacy and acceptability
of five antitubercular drugs, bedaquiline, delamanid, levofloxacin, metronidazole and moxifloxacin in the treatment
of MDR-TB. We included eleven suitable trials from nine journal articles and six clinical trials from ClinicalTrials.gov, with
data for 1472 participants. Bedaquiline (odds ratio [OR] 2.69, 95% CI 1.02-7.43), delamanid (OR 2.45, 95% CI 1.36-4.89) and
moxifloxacin (OR 2.47, 95% CI 1.01, 7.31) were significantly more effective than placebo. For efficacy, the results indicated
no statistical significance between each antitubercular drug. For acceptability, the results indicated no statistically
significant difference between each compared intervention. There is insufficient evidence to suggest that any one of the
five antitubercular drugs (bedaquiline, delamanid, levofloxacin, metronidazole and moxifloxacin) has superior efficacy
compared to the others.
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Tuberculosis (TB) has tormented humans over the cen-
turies and was a leading cause of death in Asia, Europe
and North America for centuries [1,2]. The emergence
of multidrug resistance tuberculosis (MDR-TB) and even
extensively drug tuberculosis resistant (XDR-TB) is a
major threat to global TB care and control. MDR-TB is
caused by Mycobacterium tuberculosis that is resistant to
at least isoniazid (INH) and rifampin (RMP). MDR-TB
includes the subcategory of XDR-TB, which is MDR-TB
with additional resistance to any fluoroquinolone and to
at least one of three injectable anti-TB drugs [3]. The
World Health Organization (WHO) estimates that about
450,000 new MDR-TB cases and about 170,000 MDR-
TB deaths have occurred across the world in 2012 [4].
Currently, MDR-TB treatments are not satisfactory, be-
cause of the long treatment cycle and high cost. The overall
treatment duration is at least 18 months, and requires more* Correspondence: qing@jlu.edu.cn; lifan@jlu.edu.cn
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unless otherwise stated.toxic and less effective agents than that used for drug-
susceptible TB [5]. Only 48% of patients with MDR-TB
have been successfully treated in 2010, with more patients
(52%) has been withdrawn as a reason of adverse effects
or deaths according to the World Health Organization
(WHO). Currently, second-line and third-line agents such
as ofloxacin, levofloxacin, moxifloxacin and linezolid have
been used for the treatment of MDR-TB and XDR-TB,
owing to the drug resistance of first-line antituberculosis
drugs [6]. However, some of these drugs are not recom-
mended for routine use due to variable efficacy and serious
side effects. Therefore, it is necessary to develop effective
drugs for MDR-TB treatment. Some new anti-MDR-TB
drugs are currently at various stages of clinical evaluation
or preclinical development such as bedaquiline (TMC207)
and delamanid (OPC-67683) [7]. Bedaquiline was registered
by the FDA of the United States of America in December
2012 and has been recommended for use in adults with
MDR pulmonary tuberculosis by WHO [8]. Delamanid is
awaiting approval by FDA and Pharmaceutical and Medical
Devices Agency (PMDA) of Japan [9]. In addition, existingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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being applied to the treatment of MDR-TB (Additional
file 1: Table S1) [10-12]. Some new drugs that are at an
earlier stage in the drug development pipeline such as
PA-824 and SQ109 also have shown promise. In the face
of emerging new anti-TB treatments, an important
question is regarding the assessment of the efficacy and
acceptability of these drugs, and establishment of opti-
mal treatment regimes.
The evidence derived from multiple trials and cohort
studies on MDR-TB treatment has been a subject of
much debate and has not provided useful guidance to
clinicians. Traditional meta-analyses were unable to
provide comprehensive comparisons between individual
anti MDR-TB drugs because they failed to integrate all
available randomized evidence within one analysis. Net-
work meta-analysis is a type of meta-analysis in which,
rather than simply summing up trials that have evalu-
ated the same treatment compared to placebo, different
treatments are compared by statistical inference. We
can use network meta-analysis for assessing the relative
efficacy and acceptability of new antitubercular MDR-
TB drugs, especially where there is a shortage of
pair-wise comparison of direct clinical trials of two
antitubercular drugs.
We aimed to compare the five antitubercular drugs,
bedaquiline, delamanid, levofloxacin, metronidazole, mox-
ifloxacin in the treatment of MDR-TB. Our intention was
to analyze the efficacy and acceptability of antitubercular
MDR-TB drugs by integrating all available direct and in-
direct evidence using network meta-analyses.Figure 1 Flow diagram of the study.Methods
Study selection and data collection
We did a network meta-analysis to compare five antitu-
bercular drugs for MDR-TB. We included all random-
ized trials comparing one antitubercular drug at a
therapeutic dose with other antitubercular drugs or
with placebo as oral therapy for adults with MDR-TB
before October 8, 2014. The participants were both
men and women, aged 18 years or older, and with a pri-
mary diagnosis of tuberculosis according to standard
diagnostic criteria. The patients who had sputum
culture–positive multidrug-resistant tuberculosis, with
confirmed genotypic or phenotypic resistance to isonia-
zid, rifampin, and chest radiographic findings consist-
ent with tuberculosis were diagnosed with MDR TB.
Both fixed-dose and flexible-dose designs were allowed.
We excluded trials that assess early bactericidal activity
and pharmacokinetics.
We searched Embase (http://www.elsevier.com/online-
tools/embase), Pubmed (http://www.ncbi.nlm.nih.gov/
pubmed/), ClinicalTrials.gov (http://www.clinicaltrials.gov/),the US Food and Drug Administration website (http://
www.fda.gov/) and CNKI (http://www.cnki.net/), using
the following keywords: “multidrug resistance tubercu-
losis, drug resistance tuberculosis, MDR-TB clinical,
DR-TB clinical, randomized clinical of MDR-TB, MDR-
TB treatment”. Additionally, we reviewed the meta-
analyses and publications for other potential data
sources related to antitubercular MDR-TB drugs. Study
participants were required to have a clinical diagnosis of
MDR-TB. Data extraction was performed independently
by two of the authors and checked by another. To assess
the methodological quality of included trials we used
the criteria for quality assessment recommended by the
Cochrane risk-of-bias [13], which takes into account
methodological errors arising from aspects such as allo-
cation concealment, blinding, completeness of outcome
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sources of bias.
Outcome measures
Response and dropout rates were chosen as primary
outcomes reported estimates of treatment efficacy and
acceptability. We defined response as the number of
patients whom showed sputum culture conversion to
negative. We defined treatment acceptability as the
number of patients who completed the therapy.
Statistical analysis
The whole meta-analysis in this study was divided into
two sections, including direct comparison from trad-
itional meta-analysis and indirect comparison from
network meta-analysis. We performed a traditional
meta-analysis to yield the Mantel-Haenszel odds ratio
firstly. If a trial result was presented with zero events
in one group, then the event rate was artificially in-
flated by adding 0.5; if a trial result was presented with
zero in both groups, then the data was excluded. Then,
we performed traditional meta-analysis used Stata ver-
sion 12.0 to analyze the heterogeneity of each study.
Heterogeneity between trials was quantified with the I2
and H measure. If heterogeneity was moderate or
great, we performed meta-analysis by comparing the
same interventions with a random-effects model [14].
According to the heterogeneity, we choose a random-
effects model to do the following analysis.
In addition, we performed network meta-analysis using
random-effects model in R2WinBUGS [15] in R operating
environment. We modeled the binary outcomes in everyTable 1 Characteristics of included trials
Trial Interventions Dose (mg/day) Comparator No of p
DiaconAH 2009,2012 Bedaquiline 1600,1200 placebo 47
Trail NCT00449644 Bedaquiline 1600,1200 placebo 160
Gler MT 2012 Delamanid 400,200 placebo 481
Trial NCT00685360 Delamanid 400,200 placebo 192
Zhang Q 2013 Delamanid 400,200 placebo 38
Carroll MW 2013 Metronidazole 1500 placebo 35
Trail NCT00425113 Metronidazole 1500 placebo 35
Trail NCT00082173 Moxifloxacin 400 placebo 146
Chen Y 2013 Moxifloxacin 400 placebo 74
Koh WJ 2013 Moxifloxacin 400 levofloxacin 90
Liang LL 2011 Moxifloxacin 400 levofloxacin 46
Koh WJ 2013 Levofloxacin 750 moxifloxacin 92
Liang LL 2011 Levofloxacin 600 moxifloxacin 36
BR: background drug regimen treatment, INH: isoniazid, PZA: pyrazinamide, MOX: mtreatment group of every study, and specified the relations
among the odds ratios (ORs) across studies to make differ-
ent comparisons [16]. This method combines direct and
indirect comparison for any given pair of treatments. Ana-
lyses were performed in the statistical package R 3.0.2. Fi-
nally, we analyze the fitting results and consistency of
network meta-analysis.
We also examined the pairwise comparative of effi-
cacy and acceptability among the five antitubercular
drugs. We expressed the results using bedaquiline as
reference drugs, because bedaquiline was the first new
tuberculosis drug approved by Food and Drug Admin-
istration (FDA) for MDR-TB patients [17]. This method
is an indirect comparison, and we performed this




The electronic searches yielded 245 potentially relevant
studies, of which 73 potentially eligible articles were
analyzed. We excluded 48 reports that did not meet eli-
gibility criteria (Figure 1). Overall, we used eleven trials
from 2009 to 2013 for the network meta-analysis (in-
cluding 9 journal articles and 6 clinical trials). Detailed
characteristics of all studies included in the meta-
analysis are listed in Table 1 and Table 2. The methodo-
logical quality of included trials was generally high (the
risk of bias of these clinical trials shown in Additional
file 2: Figure S1). Delamanid was evaluated in the max-
imum number of patients (711) whereas metronidazole
was evaluated in the least number (70). Moxifloxacinatients Course (weeks) Follow-up (weeks) Source
8 104 journal article [22,23]
24 104 clinical trial website [24],
study register
8 104 journal article [25], clinical
trial website [26]
8 104 journal article [27],
24 104 journal article [28]
8 24 journal article [29]
8 72 clinical trial website [30]
8 0 clinical trial website [31]
52 0 journal article [32]
12 0 journal article [33], clinical
trial website [34]
72 0 journal article [35]
12 0 journal article [33], clinical
trial website [34]
72 0 journal article [35]
oxifloxacin, EMB: ethambutol, RIF: rifampicin, OFL: ofloxacin, AMK: amikacin.
Table 2 Studies included in the network meta-analysis
Interventions No of trials Range(mg/day) Year of publication Country
Bedaquiline 2 1200-1600 2009-2012 Brazil, India, Latvia, Peru, Russian Federation, South Africa, Thailand
Delamanid 3 200-400 2012-2013 China, Egypt, Estonia, Japan, Korea, Latvia, Peru, Philippines, Cairo,
Masan, United States.
Metronidazole 2 1500 2013 Korea
Moxifloxacin 4 400 2011-2013 Brazil, Korea,China
Levofloxacin 2 600-750 2011-2013 Korea, China
Wang et al. Journal of Clinical Bioinformatics  (2015) 5:5 Page 4 of 9was evaluated in the maximum number of trials (4).
Bedaquiline and delamanid had the largest number of pa-
tient follow-ups (207 and 711 overall, respectively), whereas
moxifloxacin and levofloxacin had no follow-ups described.
Overall, 1472 individuals were randomly assigned to one of
the five antitubercular agents and were included in the net-
work meta-analysis. Figure 2 shows the network of eligible
comparisons for the network meta-analysis. 1242 individ-
uals were included in the efficacy analysis (10 trials) and
1244 in the acceptability analysis (9 trials). Most of placebo
treatment used background drug regimen treatment plus
placebo, others were not in detail. Regional disparity also
exists in treatment in background drug regimen treatments.
The mean duration of the studies was 21.1 weeks and the
mean sample size was 134 participants per group (range
35-481). Most trials were carried out in Korea (Table 2).
Direct comparisons
We extracted detailed data from eleven clinical trials to
perform analysis of efficacy and acceptability of fiveFigure 2 Network meta-analysis of eligible clinical trials of antitubercular d
trials of acceptability. The lines represent direct comparison trials, and the w
each pair of treatments, and the size of each node is proportional to the nantitubercular drugs. The possible pair wise compa-
risons between bedaquiline, delamanid, levofloxacin,
metronidazole, moxifloxacin and placebo had been
studied directly in one or more trials. Figure 3 and 4
shows the odds ratios for each of these direct compari-
sons. The direct comparisons (Figure 3) showed that in
terms of efficacy, results derived from these drug com-
parisons showed no statistical significance at the 95%
confidential interval if the pooled OR included 1. For
acceptability (Figure 4), none of the comparisons had
significance.
Overall, heterogeneity was moderate, although for
some comparisons the 95% CI included values that
showed low, moderate or no heterogeneity, reflecting
the small number of included studies for each pair-
wise comparison. In the meta-analyses of direct com-
parisons of efficacy, we found that 2 values were a little
higher for the comparisons delamanid vs. placebo and
moxifloxacin vs. placebo, (I2 = 51.9% and 47.1% re-
spectively). There was no heterogeneity between therugs for MDR-TB. A: Eligible clinical trials of efficacy; B: Eligible clinical
idth of the lines is proportional to the number of trials comparing
umber of randomised participants (sample size).
Figure 3 Direct comparisons of efficacy between each pair of antitubercular treatment. The short horizontal represent credibility interval, the
cube located in the middle of the horizontal represent odds ratio. The midcourt line represent OR = 1. The rhombus in the final of each studies
indicated aggregated results of all the clinical trials. The short horizontal or rhombus was intersected with midcourt line means no significant
difference. The short horizontal or rhombus was on the midcourt line’s left means the placebo was more effective.
Wang et al. Journal of Clinical Bioinformatics  (2015) 5:5 Page 5 of 9
Figure 4 Direct comparisons of acceptability between each pair of antitubercular treatment. The short horizontal represent credibility interval, the
cube located in the middle of the horizontal represent odds ratio. The midcourt line represent OR = 1. The rhombus in the final of each studies
indicated aggregated results of all the clinical trials. The short horizontal or rhombus was intersected with midcourt line means no significant
difference. The short horizontal or rhombus was on the midcourt line’s left means the placebo was more acceptable.
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levofloxacin vs. moxifloxacin (I2 = 0.0%). The following
one comparisons had only a single trial and therefore
heterogeneity could not be evaluated (Figure 3). In the
meta-analyses of acceptability, no heterogeneity was
found in all the comparisons (Figure 4).
Indirect comparisons
Figure 5 shows the results of indirect comparisons and the
OR was the basis for determining effect size [16,19]. Indir-
ect comparisons could provide pair-wise comparisons
when no clinical randomized controlled trials are avail-
able. No statistically significant difference was found be-
tween bedaquiline, delamanid, levofloxacin, metronidazole
and moxifloxacin. In terms of acceptability, there was no
statistically significant difference between each of the
compared interventions. We used R2Winbugs to con-
duct the convergence assessment of model (Additional
file 3: Figure S2). The parameter totresdev assessed
model fit in our statistic method.
We used placebo and bedaquiline as reference com-
pounds to analyze the efficacy and acceptability of the
five antituberculosis drugs. With efficacy of placebo as
the standard of comparison, bedaquiline, delamanid
and moxifloxacin indicated statistically more effective
than placebo (Additional file 4: Figure S3A). With
bedaquiline as the standard of comparison, there have
no significant difference between these five antituber-
culosis drugs (Additional file 5: Figure S4A). With ac-
ceptability of placebo and bedaquiline as the standard
of comparison, there was no obvious difference be-
tween the interventions (Additional file 4: Figure S3B
and Additional file 5: Figure S4B).
Discussion
Our analysis was based on eleven clinical trials that
included 1472 individuals who had been randomlyFigure 5 Efficacy and acceptability of the five antituberculosis drugs. Drugs are
read from left to right. Results are presented as comparisons of ORs the in the h
columns. For efficacy, ORs higher than 1 means the upper-left drug was more e
was more acceptable. Significant results are in bold and underscored. OR =Oddassigned to five antituberculosis drugs used to treat
MDR-TB. Our findings might help to choose the most
efficacious and acceptable drug among the antitubercu-
losis drugs used for treatment of MDR-TB. Some anti-
tuberculosis drugs showed differences in terms of
statistical and clinical significance. In terms of re-
sponse, there was no statistically significant difference
in terms of the efficacy and acceptability among these
five antituberculosis drugs.
Levofloxacin and moxifloxacin which belongs to
fluoroquinolones are the only two drugs that have been
directly compared (apart from placebo) among the five
antituberculosis drugs. Based on a retrospective ana-
lysis, Lee J and co-workers [20] reported that both
levofloxacin and moxifloxacin showed equivalent effi-
cacy for treating MDR-TB. Furthermore, Jiang RH et
al, indicated that levofloxacin was similar to moxifloxa-
cin in terms of efficacy when used for the treatment of
MDR-TB [21]. In the current study, we also found that
there was no significant difference between levofloxa-
cin and moxifloxacin in treating MDR-TB (Figure 5).
Inevitably, several limitations are associated with our
study. First, most of the antituberculosis drugs for
MDR-TB were still in Phase I, II or III clinical trials
and therefore the number of eligible articles was limited.
The sample size of studies was generally small and most of
them comprised of less than 50 patients (Table 1). Al-
though the heterogeneity of comparisons in some trials ap-
peared to be moderate, sample size was not large enough
to make any conclusions concerning the equivalence of
these effects. Second, for the eligible records, most clinical
trials compared drugs with placebo, and those which made
direct comparisons between the five antituberculosis drugs
was very limited (Figure 2).Third, many studies dealt with
a heterogeneous population of MDR-TB patients who were
resistant to different antibiotics and therefore this may
have an impact on the result. Fourth, the durationreported in alphabetical order. Comparisons between drugs should be
orizontal treatment rows compared with the ORs in the vertical treatment
ffective. For acceptability, ORs higher than 1 means the lower-right drug
s ratio. CI = credibility interval.
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The duration of the treatment course was in the range of 8
to 72 weeks (Table 1). Finally, we chose 8-24 weeks as the
time period during which sputum culture-conversion was
assessed. However, it is possible that some patients may
still be receiving treatment during this time. For some tri-
als, the result was displayed in mean times of sputum
culture-conversion, and it may show no difference between
drug and placebo groups at 8-24 weeks.Conclusion
There is insufficient evidence to suggest that any one of the
five antitubercular drugs (bedaquiline, delamanid, levofloxa-
cin, metronidazole and moxifloxacin) has superior efficacy
compared to the others. Further randomized controlled tri-
als are needed to verify and confirm this conclusion. In the
future, our research will focus on the emergence of new
studies, especially large-sample studies.Additional files
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